A Novel SNP Associated with Nighttime Pulse Pressure in Young-Onset Hypertension Patients Could Be a Genetic Prognostic Factor for Cardiovascular Events in a General Cohort in Taiwan

Leu, Hsin Bang; Chung, Chia Min; Lin, Shing Jong; Lu, Tse Min; Yang, Hsin-Chou; Ho, Hung Yun; Ting, Chih Tai; Lin, Tsung-Hsien; Sheu, Sheng Hsiung; Tsai, Wei Chuan; Chen, Jyh Hong; Yin, Wei Hsian; Chiu, Tai‐Yuan; Chen, Chin Iuan; Pan, Wen Harn; Chen, Jaw Wen

doi:10.1371/journal.pone.0097919

Cited by 9 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Devices used included ambulatory heart rate monitors, electrocardiographs, ambulatory blood pressure monitor, implantable cardioverter-defibrillators, and pressure sensors. Mobile cardiac biomarkers were used to measure study outcomes among patients with atrial fibrillation [ 37 ], heart failure [ 38 ], hypertension [ 39 ], and myocardial infarctions [ 31 ], as well as patients who had undergone kidney transplant surgery [ 33 ]. The mobile cardiac biomarkers were used to measure either primary or co-primary study endpoints in 4 observational studies [ 33 , 37 , 39 , 40 ] and exploratory endpoints in 2 observational studies [ 31 , 38 ] (see online suppl.…”

Section: Resultsmentioning

confidence: 99%

Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review

et al. 2018

View full text Add to dashboard Cite

Background: The use of mobile devices in clinical research has advanced substantially in recent years due to the rapid pace of technology development. With an overall aim of informing the future use of mobile devices in interventional clinical research to measure primary outcomes, we conducted a systematic review of the use of and clinical outcomes measured by mobile devices (mobile outcomes) in observational and interventional clinical research. Method: We conducted a PubMed search using a range of search terms to retrieve peer-reviewed articles on clinical research published between January 2010 and May 2016 in which mobile devices were used to measure study outcomes. We screened each publication for specific inclusion and exclusion criteria. We then identified and qualitatively summarized the use of mobile outcome assessments in clinical research, including the type and design of the study, therapeutic focus, type of mobile device(s) used, and specific mobile outcomes reported. Results: The search retrieved 2,530 potential articles of interest. After screening, 88 publications remained. Twenty-five percent of the publications (n = 22) described mobile outcomes used in interventional research, and the rest (n = 66) described observational clinical research. Thirteen therapeutic areas were represented. Five categories of mobile devices were identified: (1) inertial sensors, (2) biosensors, (3) pressure sensors and walkways, (4) medication adherence monitors, and (5) location monitors; inertial sensors/accelerometers were most common (reported in 86% of the publications). Among the variety of mobile outcomes, various assessments of physical activity were most common (reported in 74% of the publications). Other mobile outcomes included assessments of sleep, mobility, and pill adherence, as well as biomarkers assessed using a mobile device, including cardiac measures, glucose, gastric reflux, respiratory measures, and intensity of head-related injury. Conclusion: Mobile devices are being widely used in clinical research to assess outcomes, although their use in interventional research to assess therapeutic effectiveness is limited. For mobile devices to be used more frequently in pivotal interventional research – such as trials informing regulatory decision-making – more focus should be placed on: (1) consolidating the evidence supporting the clinical meaningfulness of specific mobile outcomes, and (2) standardizing the use of mobile devices in clinical research to measure specific mobile outcomes (e.g., data capture frequencies, placement of device). To that aim, this manuscript offers a broad overview of the various mobile outcome assessments currently used in observational and interventional research, and categorizes and consolidates this information for researchers interested in using mobile devices to assess outcomes in interventional research.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Primary endpoint is major cardiovascular events including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and revascularization procedures including coronary intervention and bypass surgery. The protocol for CV event follow-up was similar to that previously reported 5,9,10 .…”

Section: Methodsmentioning

confidence: 94%

The benefit of secondary prevention with oat fiber in reducing future cardiovascular event among CAD patients after coronary intervention

Leu

Yin

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

There is limited information about the association between oat fiber intake and future cardiovascular events in CAD patients after coronary intervention for secondary prevention. This study enrolled 716 patients after coronary intervention in clinical stable status from the CAD cohort biosignature study. Patients were analyzed according to whether the presence of regular oat fiber intake during the follow-up period, and the association with endpoints including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and revascularization procedures were analyzed. The average follow-up period is 26.75 ± 8.11 months. Patients taking oat fiber were found to have lower serum levels of LDL, triglycerides, ratio of TC/HDL, as well as lower inflammatory markers values. After adjusting for confounders in the proportional hazard Cox model, oat fiber intake was associated with a lower risk of future revascularization (HR = 0.54, 95% CI 0.35–0.85; p = 0.007), and lower risk of major adverse cardiovascular events (HR = 0.62, 95% CI 0.43–0.88; p = 0.008), suggesting the association of oat fiber use and lower risk of future adverse event in CAD patients after coronary intervention.

show abstract

“…Stroke is confirmed if there is a new neurologic deficit lasting for at least 24 h with definite imaging evidence of cerebrovascular accident either by MRI or CT scan. The protocol for CV event follow-up is similar to that has been reported in our previous works [ 10 , 11 ]. Besides, for the second track of long-term follow-up, the assessment of clinical events will be also conducted by some independent national data banks if the patients agree.…”

Section: Methodsmentioning

confidence: 95%

Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan

Leu

Yin

Tseng

et al. 2017

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

BackgroundEither classic or novel biomarkers have not been well investigated for clinical outcomes of coronary artery disease (CAD) in Asian people especially ethnic Chinese. We reported here a prospective national-based follow-up study that aims to elucidate the clinical profiles and to identify the new biosignatures (especially the non-lipid profile and inflammatory biomakers) for future clinical outcomes in a sizable cohort of stable CAD patients in Taiwan.MethodsA total of 2500 CAD patients under stable condition after successful percutaneous coronary intervention will be enrolled for clinical data collection and blood/urine sampling in northern, southern, western, or eastern part of Taiwan between 2012 and 2017. They will be regularly followed up at least annually for 5 years to assess all cause deaths, hard clinical events (including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), and total cardiovascular events (including hard events, unplanned revascularization procedures, unplanned hospitalization for refractory or unstable angina, and for other causes such as stroke, transient ischemic attack, heart failure, or peripheral arterial occlusive disease). The classic and newly defined biosignatures will be compared in patients with and without clinical events during follow-up. The novel biomarkers will be identified via metabolomics analyses. Additionally, psychological personality and lifestyle data will be incorporated to explore the new dimensional views of the complex mechanisms of the disease. Till December 2014, the initial 1663 patients have been successfully enrolled. Among them, 85.93% are male; 36.22% have type 2 diabetes; 64.82% have hypertension; 56.04% are smokers and 20.44% have a family history of CAD. Their lipid profiles are under contemporary medical control with a mean plasma total cholesterol level of 163.51 ± 36.99 mg/dL and a mean low-density lipoprotein cholesterol level of 95.21 ± 29.98 mg/dL.DiscussionThis nationwide study has successfully started to update the contemporary information and to investigate the potential predictors for clinical outcomes of stable CAD patients in Taiwan. The identification of new biomarkers, lifestyle and psychological personality may help to elucidate the complex mechanisms and provide the novel rational to the individual treatment strategies in Asian especially ethnic Chinese patients with CAD.

show abstract

A Novel SNP Associated with Nighttime Pulse Pressure in Young-Onset Hypertension Patients Could Be a Genetic Prognostic Factor for Cardiovascular Events in a General Cohort in Taiwan

Cited by 9 publications

References 32 publications

Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review

Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review

The benefit of secondary prevention with oat fiber in reducing future cardiovascular event among CAD patients after coronary intervention

Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan

Contact Info

Product

Resources

About